Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
264 results about "Mucin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Mucins (/ˈmjuːsɪn/) are a family of high molecular weight, heavily glycosylated proteins (glycoconjugates) produced by epithelial tissues in most animals. Mucins' key characteristic is their ability to form gels; therefore they are a key component in most gel-like secretions, serving functions from lubrication to cell signalling to forming chemical barriers. They often take an inhibitory role. Some mucins are associated with controlling mineralization, including nacre formation in mollusks, calcification in echinoderms and bone formation in vertebrates. They bind to pathogens as part of the immune system. Overexpression of the mucin proteins, especially MUC1, is associated with many types of cancer.
Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
Owner:UNIVERSITY OF KENTUCKY
Methods to identify agents modulating functions of polypeptide galnac-transferases, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments
Novel methods for identification of inhibitors or modulators of binding activities mediated by lectin domains of polypeptide GalNAc-transferases are disclosed. Direct binding activity of GalNAc-transferase lectins has been demonstrated for the first time and methods to measure lectin mediated binding of isolated lectins or enzymes with lectin domains are disclosed. The present invention specifically discloses a novel selective inhibitor of polypeptide GalNAc-transferase lectin domains, which provides a major advancement in that this inhibitor and related inhibitors sharing common characteristics of activity bind lectin domains without serving as acceptor substrate for glycosyltransferases involved in synthesis of O-glycans. This inhibitor is represented by the β-anomeric configuration of GalNAc-benzyl, GalNAcβ-benzyl. Methods for inhibiting intracellular transport, cell surface expression, and secretion of mucins and O-glycosylated glycoproteins without affecting O-glycosylation processing are disclosed using the novel selective inhibitor identified.
Owner:GLYCOZYM
Isolation and Cultivation of Stem/Progenitor Cells From the Amniotic Membrane of Umbilical Cord and Uses of Cells Differentiated Therefrom
The present invention relates to a skin equivalent and a method for producing the same, wherein the skin equivalent comprises a scaffold and stem / progenitor cells isolated from the amniotic membrane of umbilical cord. These stem / progenitor cells may be mesenchymal (UCMC) and / or epithelial (UCEC) stem cells, which may then be further differentiated to fibroblast and keratinocytes. Further described is a method for isolating stem / progenitor cells from the amniotic membrane of umbilical cord, wherein the method comprises separating the amniotic membrane from the other components of the umbilical cord in vitro, culturing the amniotic membrane tissue under conditions allowing cell proliferation, and isolating the stem / progenitor cells from the tissue cultures. The invention also refers to therapeutic uses of these skin equivalents. Another aspect of the invention relates to the generation of a mucin-producing cell using stem / progenitor cells obtained from the amniotic membrane of umbilical cord and therapeutic uses of such mucin-producing cells. In yet another aspect, the invention relates to a method for generating an insulin-producing cell using stem / progenitor cells isolated from the amniotic membrane of umbilical cord and therapeutic uses thereof. The invention further refers to a method of treating a bone or cartilage disorder using UCMC. Furthermore, the invention refers to a method of generating a dopamin and tyrosin hydroxylase as well as a HLA-G and hepatocytes using UCMC and / or UCEC. The present invention also refers to a method of inducing proliferation of aged keratinocytes using UCMC.
Owner:CELLRESEARCH CORP PTE LTD
Anti-Pancreatic Cancer Antibodies
InactiveUS20090304580A1Strong specificityHigh sensitivityPeptide/protein ingredientsNanomedicineAntigenPancreatic tissue
Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful therapeutic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection, diagnosis and / or treatment of cancer, such as pancreatic cancer. The antibodies, such as PAM4 antibodies, bind to a PAM4 antigen that shows unique cell and tissue distributions compared with other known antibodies such as CA19.9, DUPAN2, SPAN1, Nd2, B72.3, and Lea and Le(y) antibodies that bind to the Lewis antigens.
Owner:IMMUNOMEDICS INC
Mucin synthesis inhibitors
The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds of Formula II in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.whereinX is S, N, O or CR;Y is CRR′, O, NR6, CRR′—CRR′ or CR═CR;Z is NR6, O, S, CRR′ or CRR′—CRR′;R1-R3 are independently selected from the group consisting of H, C1-C8 alkyl, C1-C8 alkoxy, amino, hydroxy, halosubstituted alky and halo;R4 isQ is CR, NR6 orR5 is H or benzyl;R6 is H, C1-C8 alkyl, C1-C8 alkoxy, OH or halo; andR and R′ are independently H, C1-C8 alkyl, C1-C8 alkoxy, OH or halo,or a pharmaceutically acceptable salt thereof.
Owner:GENAERA CORP
Method for separating and purifying sea-mussel mucin by using mixing adsorption chromatography
ActiveCN101348520AOvercoming the problem of low yieldHigh yieldPeptide preparation methodsAnimals/human peptidesHigh concentrationChromatographic separation
The invention relates to a method for separating and purifying mussel mucin by using a mixed adsorption chromatography. Mussel mucin contains a group of L-3,4- -Dihydroxyphenylalanine (L-DOPA), a phenohydroxyl group thereof can act as the supplier for hydrogen bond, the benzene ring thereof can generate a hydrophobic effect, and the lysine thereof with strong positive charges is capable of forming a static bond. On the basis of the properties of mussel mucin, a mixed adsorption chromatography (i.e. the adsorption chromatography based on three principles of adsorption with hydrogen bond, adsorption with hydrophobic effect, and static adsorption) is adopted to overcome the problem of low yielding rate of mussel mucin in the prior art for separating and purifying mussel mucin. An strong acid extraction is adopted to eliminate small-molecular compounds from a desalting column, an argar medium with high concentration and high cross-linking degree to separate and purify mussel mucin, and an acetic acid-urea- polyacrylamide gel electrophoresis is used to differentiate mussel mucin through specific chromogenesis with nitro blue tetrazolium. Three principles adopted with one separation medium to separate mussel mucin achieve high selectivity, simplify the purification technology, and decrease production cost.
Owner:JIANGYIN USUN BIOCHEMICAL TECH CO LTD
Method for separating and purifying sea-mussel mucin by using salting out and dialyzing
ActiveCN101585874ALow costIncrease concentrationPeptide preparation methodsAnimals/human peptidesHigh concentrationPurification methods
The invention relates to a method for separating and purifying the sea-mussel mucin by using salting out and dialyzing, the salting out and the dialyzing utilizes the proteinaceous physicochemical character to purify by a non- chromatograph method, and solves the problem of high apparatus and material cost in the chromatograph method for purifying the sea-mussel mucin, a quick, low-cost and high-concentration method for separating and purifying the sea-mussel mucin is provided. The strong acid is used for extracting, the salting out and the dialyzing are used for purifying, the sea-mussel mucin is determined by adopting the acetic acid-carbamide- polyacrylamide gel electrophoresis via the blue tetrazolium specificity colour development, and the purity is determined by the inversed phase chromatography quantitatively.
Owner:JIANGYIN USUN BIOCHEMICAL TECH CO LTD
Method for purification of viral vectors having proteins which bind sialic acid
ActiveUS7319002B2Method be rapidMethod is fastBioreactor/fermenter combinationsBiological substance pretreatmentsBinding siteViral vector
A method for isolating, from a mixture, a virus having a surface protein with a binding site for sialic acid is provided. The method involves contacting the mixture with mucin which has been linked to a solid support and washing the solid support to remove material from the mixture is non-specifically bound to the mucin-linked support. Thereafter, the specifically bound virus (e.g., AAV4 or AAV5) may be removed in a further washing step utilizing a concentrated slat or solution with low pH. Also described are pharmaceutical kits containing solid supports linked to mucin for use in isolating virus having a surface protein with a binding site for sialic acid, or detecting the presence of the virus in a biological sample.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1
Extraction method and apparatus for high-sensitivity body fluid testing device
ActiveUS20080166820A1Rapid and efficient mannerQuick and accurate testBioreactor/fermenter combinationsBiological substance pretreatmentsBottleSaliva
An extraction method and apparatus is provided for obtaining quick, safe and highly sensitive testing of any of a variety of body fluids including saliva, blood, urine or other fluids for drugs of abuse or other analytes. The apparatus includes a latchable extraction wand for obtaining body fluid samples from a subject which is adapted to maximize the portion of the body fluid sample that will go into a graduated bottle containing a buffer solution, and a testing device wherein the sample will be received and into which test strips can be inserted to determine levels of drugs of abuse or other analyte in the sample. In one of the methods of the invention, energy is imparted to the sample and buffer solution, such as by shaking, and this facilitates the reduction of sample viscosity, such as by promoting the breakdown of mucins when the sample is saliva.
Owner:HEALGEN SCI LLC
Product containing Lactobacillus reuteri strain ATTC PTA-4965 or PTA-4964 for inhibiting bacteria causing dental caries
InactiveUS6872565B2Reduce in quantityPrevent and reduce and treat dental cariesAntibacterial agentsCosmetic preparationsBacteroidesBacilli
Strains of Lactobacillus that have been selected for their capability of reducing the number of Streptococcus mutans in the mouth of mammals through inhibiting activity in combination with good binding to the oral mucins and dental plaque, Administering the strains in a product such as food, reduces and treats dental caries. Preferred strains are Lactobacillus reuteri strain ATTC PTA-4965 or Lactobacillus reuteri strain ATTC PTA-4964.
Owner:BIOGAIA AB
Skin equivalents derived from umbilical cord mesenchymal stem/progenitor cells and umbilical cord epithelial stem/progenitor cells
Owner:CELLRESEARCH CORP PTE LTD
Apparatus for high-sensitivity body fluid testing device
ActiveUS7695953B2Rapid and efficient mannerQuick and accurate testBioreactor/fermenter combinationsBiological substance pretreatmentsBottleSaliva
An extraction method and apparatus is provided for obtaining quick, safe and highly sensitive testing of any of a variety of body fluids including saliva, blood, urine or other fluids for drugs of abuse or other analytes. The apparatus includes a latchable extraction wand for obtaining body fluid samples from a subject which is adapted to maximize the portion of the body fluid sample that will go into a graduated bottle containing a buffer solution, and a testing device wherein the sample will be received and into which test strips can be inserted to determine levels of drugs of abuse or other analyte in the sample. In one of the methods of the invention, energy is imparted to the sample and buffer solution, such as by shaking, and this facilitates the reduction of sample viscosity, such as by promoting the breakdown of mucins when the sample is saliva.
Owner:HEALGEN SCI LLC
Tumor antigenic polypeptide and application thereof as tumor vaccine
The invention provides a human mucin-1 tumor antigenic polypeptide with an amino acid sequence shown in SEQ ID NO: 1 or variants thereof, wherein the polypeptide can be combined with an HLA (Human Leukocyte Antigen) I and can be recognized by a cell CD8<+>T. The invention further provides nucleic acids coding the polypeptide. The invention further provides an antigen presenting cell capable of presenting the polypeptide on the surface of the cell and an immune effector cell capable of recognizing the polypeptide or antigen presenting cell. The invention further provides application of the polypeptide or variants thereof, the nucleic acids, the antigen presenting cell or the immune effector cell in the preparation of vaccines or pharmaceutical compositions for treating or preventing cancer. Tumor vaccines provided by the invention have a good treatment effect on relatively large crowds and are particularly applicable to the Asian, e.g. Chinese.
Owner:BEIJING ZHIFEI LVZHU BIOPHARM +1
Therapeutic use of mucin glycans
InactiveUS20140187474A1Enhance maintain growthAdequate doseBiocideSaccharide peptide ingredientsGlycanIntensive care medicine
A therapeutic formulation containing mucin glycans derived from one or a number of nutritionally appropriate sources is described.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Biomarkers for pancreatic cancer and diagnostic methods
ActiveUS20110257029A1Improve performanceHigh sensitivityPeptide librariesLibrary screeningAntigenBiomarker (petroleum)
Methods and related kits for differentiating pancreatic cancer from a benign pancreatic disease. The method includes assaying a patient biological sample for a total level of CA 19-9 antigen and for a glycan level in specific mucin(s), and comparing the total level of CA 19-9 antigen and the glycan level in the specific mucin(s) to statistically validated thresholds, wherein a different level of total CA 19-9 antigen in the patient biological sample as compared to a statistically validated threshold and a different level of glycan level in the specific mucin(s) as compared to statistically validated thresholds indicate pancreatic cancer in the patient rather than a benign pancreatic disease.
Owner:UNIVERSITY OF PITTSBURGH +1
Hemostasis composite material based on chitosan and marine mussel mucin and preparation method of hemostasis composite material
InactiveCN105477674AExcellent new hemostatic effectSoft textureAbsorbent padsBandagesBiologyBiomedical engineering
The invention relates to a hemostasis composite material based on chitosan and marine mussel mucin and a specific preparation method of the hemostasis composite material. The hemostasis composite material comprises a chitosan type hydrogel carrier and the marine mussel mucin guided into the chitosan type hydrogel carrier. The hemostasis composite material is soft in texture, high in application performance, applicable to hemostasis of body-surface wounds and bleeding of parts such as internal tissue and organs, and excellent in hemostasis effect.
Owner:北京铂铱电气科技有限公司 +2
Nanoparticle Based Therapy for Dispersing Mucin
InactiveUS20110135744A1Reduced availabilityPrevent gel formationPowder deliveryDispersion deliveryNanoparticleActin
There are provided compositions and methods to disperse mucin and / or actin using nanoparticles wherein the average diameter of the nanoparticles is less than about 1000 nm.
Owner:RGT UNIV OF CALIFORNIA
Yeast-muc1 immunotherapeutic compositions and uses thereof
ActiveUS20130315941A1Improve survivalReduce the burden onTetracycline active ingredientsMucinsYeastCancer research
Owner:GLOBE IMMUNE INC +1
Anti-mucin antibodies for early detection and treatment of pancreatic cancer
InactiveUS20140227179A1Strong specificityHigh sensitivityUltrasonic/sonic/infrasonic diagnosticsOrganic active ingredientsEpitopeSerum samples
Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to an epitope located within the second to fourth cysteine-rich domains of MUC5ac (amino acid residues 1575-2052) and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.
Owner:IMMUNOMEDICS INC
Selection and use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries
InactiveUS20050002874A1Reduce in quantityImprove bindingCosmetic preparationsBiocideCementum cariesMammal
New strains of Lactobacillus that have been selected for their capability of improved reduction the number of Streptococcus mutans in the mouth of mammals through inhibiting activity in combination with better binding to the oral mucins and dental plaque, thereby preventing, reducing or treating dental caries, and products derived from said strains, including agents for treatment or prophylaxis of caries for administration to humans.
Owner:BIOGAIA AB
Extracting process for purple sweet potato antocynidin and mucin
The extraction process of purple sweet potato anthocynidin and mucin includes the following steps: washing fresh or dry sweet potato, crushing, extracting in acid aqua, precipitation to eliminate starch and dregs, precipitating the supernatant with edible flocculant to obtain protein and polysaccharide, filtering, column adsorption of the filtrate, elution with acid methanol solution, decompressio concentration, and vacuum drying or spray drying to obtain product. Adopting acid solution extraction and flocculating mucinw ith flocculant to solve the filtering problem effectively, so that the present invention makes it possible to obtain anthocynidin and mucin simultaneously and has high anthocynidin purity and low production cost.
Owner:SOUTHWEST UNIVERSITY
Method for extracting snail slime extract containing active enzymes
The invention belongs to the field of extraction of snail slime and particularly relates to a method for extracting snail slime extract containing active enzymes. Snail slime comprises proteins, the active enzymes, mucin, chondroitin sulfate, protein polysaccharides and hydroxyacetic acid; the active enzymes include cellulase, pectinase, amylase and protease. The method comprises the following steps: collecting the snail slime with the active enzymes by utilizing an extraction device; hydrolyzing the collected snail slime with the active enzymes; separating the hydrolyzed snail slime containing the active enzymes to obtain extract liquor of the snail slime; crystallizing the separated extract liquor of the snail slime. The extract is high in quality.
Owner:南通禹丰迪生物科技有限公司
Prolongation of chemical activity of flavorants and therapeutics with cetyl pyridinium chloride
InactiveUS6207192B1Good effectShorten application timePowder deliverySolution deliveryCoated surfaceFlavor
Cetyl pyridinium chloride and other amphiphilic substances may be mixed with flavorants or therapeutics in accompaniment with such as bulking agents or sweeteners in order to prolong their duration of action at the site of attachment, which is a mucin coated surface for the purpose of providing the consumer with a more efficacious product.It is the concept of delayed dispensing that is the invention, the product being dispensed is only an illustration of the best mode.
Owner:CALFEE HALTER & GRISWOLD
Therapeutic use of mucin glycans
ActiveUS20120207882A1Promote mucus-adapted beneficial memberPromote growthMilk preparationSugar derivativesGlycanIntensive care medicine
A therapeutic formulation containing mucin glycans derived from one or a number of nutritionally appropriate sources is described.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Mucin antigen vaccine
Owner:MICROVAX LLC
O-glycans in the treatment of inflammatory bowel disease and cancers
The present invention provides preventive approaches and treatments for an inflammatory bowel disorder (e.g., Crohn's disease or ulcerative colitis) or a gastrointestinal tumor (e.g., a colorectal cancer) comprising administering an O-glycan composition (e.g., mucins) to a subject, such as a human patient. In addition, the present invention also provides transgenic mice that fail to synthesize core 1-derived or core 3-derived O-glycans.
Owner:OKLAHOMA MEDICAL RES FOUND
Fine dried noodles added with Chinese yam powder, pumpkin powder and millet flour, and preparation method of fine dried noodles
InactiveCN106387663AIncrease health functionPromote digestion and absorptionFood ingredient as mouthfeel improving agentVitamin CFood material
The invention provides fine dried noodles added with Chinese yam powder, pumpkin powder and millet flour, and a preparation method of the fine dried noodles. The fine dried noodles are made from the following raw materials in parts by weight: 75-85 parts of wheat flour, 10-15 parts of Chinese yam powder, 4-8 parts of pumpkin powder, 4-8 parts of millet flour, 2-3 parts of vital wheat gluten, 0.005-0.01 part of vitamin C, 26-32 parts of water, 2-3 parts of table salt and 0.08-0.1 part of CSL-SSL. In the fine dried noodles added with the Chinese yam powder, the pumpkin powder and the millet flour disclosed by the invention, the Chinese yam contains rich mucin, amylase, saponin, polyphenol oxide and the like, and has good health-care functions for human bodies; pumpkins contain pumpkin polysaccharide, carotenoid and pectin, and are a good vegetable extremely beneficial to the human bodies; millet contains excellent protein and rich mineral substances; and after food materials of the Chinese yam, the pumpkins and the millet are added, the nutrients of the fine dried noodles are more balanced.
Owner:宜垦(天津)农业制品有限公司
Enzymatic large-scale synthesis of mucin glyconjugates, and immunogenic applications thereof
InactiveUS20100272707A1Promote effectiveRaise the ratioMicrobiological testing/measurementMucinsImmunogenicityGlycoconjugate
The present invention relates to mucin glycoconjugates, and to a process of producing mucin glycoconjugates. It relates to the biological, pharmaceutical and medical applications thereof. The invention notably provides mucin glycoconjugates which do not require a protein carrier, such as KHL, to induce an immune response (anti-Tn IgG).
Owner:INST PASTEUR +2
Biomarkers for the detection and screening of down syndrome
InactiveUS20120288873A1Nervous disorderMaterial analysis by observing effect on chemical indicatorBile fluidBiology
The disclosure includes assays and methods for screening for risk of Down syndrome and / or trisomy 21 in a fetus. The assays and methods comprise determining the level of at least one biomarker selected from mucin 13 (MUC13), bile salt-activated lipase (CEL), dipeptidyl peptidase 4 (DPP4), carboxypeptidase A1 (CPA1), amyloid precursor protein (APP) and tenascin-C (TNC-C) polypeptides in a test biological sample from a pregnant subject, wherein a decreased level of MUC13, CEL, DPP4, and / or CPA1 polypeptide and / or an increased level of APP and / or TNC-C polypeptide in the test biological sample compared to a corresponding reference biomarker polypeptide level indicates an increased risk of Down syndrome or trisomy 21 in the fetus. The disclosure also includes assays, compositions, immunoassays, and kits for performing the methods disclosed herein.
Owner:UNIV HEALTH NETWORK
Compositions derived from stem cell released molecules & methods for formulation thereof
InactiveUS20140205563A1Ensuring structureEnsure stabilityBiocideCosmetic preparationsFibroblastic cellCytokine
Compositions for use in treatment of a variety of tissue diseases include stem cells and stem cell released molecules (SRM's) suspended in an aqueous solution with a cellulosic material or other thickening agent. The stem cells and SRM's can be derived from one or more distinct cell lines. The SRM's can further include one or more mucins, cytokines, or growth factors. Exemplary formulations include stem cells and SRMs derived from epithelial stem cells, corneal limbal stem cells, and fibroblasts. Other compositions and methods for formulation thereof are described.
Owner:BIOREGENERATIVE SCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com